- Home
- SRG vs ABEO Comparison
SRG vs ABEO Comparison
Compare SRG & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | ABEO |
|---|---|---|
| Founded | 2015 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.5M | 282.5M |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SRG | ABEO |
|---|---|---|
| Price | $1.62 | $4.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 136.6K | ★ 1.1M |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.90 | ★ 165.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,204,000.00 | $2,998,000.00 |
| Revenue This Year | N/A | $804.33 |
| Revenue Next Year | N/A | $119.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.30 | ★ 258.18 |
| 52 Week Low | $1.55 | $4.00 |
| 52 Week High | $4.33 | $7.65 |
Technical Indicators
Market Signals| Indicator | SRG | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 33.10 |
| Support Level | $1.56 | $4.26 |
| Resistance Level | $1.71 | $5.83 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 48.84 | 12.50 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.